These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24497539)

  • 1. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.
    Pulsipher MA; Langholz B; Wall DA; Schultz KR; Bunin N; Carroll WL; Raetz E; Gardner S; Gastier-Foster JM; Howrie D; Goyal RK; Douglas JG; Borowitz M; Barnes Y; Teachey DT; Taylor C; Grupp SA
    Blood; 2014 Mar; 123(13):2017-25. PubMed ID: 24497539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).
    Pulsipher MA; Wall DA; Grimley M; Goyal RK; Boucher KM; Hankins P; Grupp SA; Bunin N
    Br J Haematol; 2009 Dec; 147(5):691-9. PubMed ID: 19744131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Alyea EP; Li S; Kim HT; Cutler C; Ho V; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):920-6. PubMed ID: 18640576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.
    Shayani S; Palmer J; Stiller T; Liu X; Thomas SH; Khuu T; Parker PM; Khaled SK; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2013 Feb; 19(2):298-304. PubMed ID: 23078784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.
    Cutler C; Logan B; Nakamura R; Johnston L; Choi S; Porter D; Hogan WJ; Pasquini M; MacMillan ML; Hsu JW; Waller EK; Grupp S; McCarthy P; Wu J; Hu ZH; Carter SL; Horowitz MM; Antin JH
    Blood; 2014 Aug; 124(8):1372-7. PubMed ID: 24982504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.
    Khimani F; Kim J; Chen L; Dean E; Rizk V; Betts B; Nishihori T; Locke F; Mishra A; Perez L; Ayala E; Kharfan-Dabaja M; Nieder M; Fernandez H; Anasetti C; Pidala J
    Bone Marrow Transplant; 2017 Jul; 52(7):1003-1009. PubMed ID: 28368376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.
    Ringdén O; Remberger M; Dahllöf G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
    Eur J Haematol; 2011 Dec; 87(6):503-9. PubMed ID: 22974354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
    Snyder DS; Palmer J; Gaal K; Stein AS; Pullarkat V; Sahebi F; Vora N; Nakamura R; Forman SJ
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial.
    Armand P; Kim HT; Sainvil MM; Lange PB; Giardino AA; Bachanova V; Devine SM; Waller EK; Jagirdar N; Herrera AF; Cutler C; Ho VT; Koreth J; Alyea EP; McAfee SL; Soiffer RJ; Chen YB; Antin JH
    Br J Haematol; 2016 Apr; 173(1):96-104. PubMed ID: 26729448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
    Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
    Labrador J; López-Corral L; López-Godino O; Vázquez L; Cabrero-Calvo M; Pérez-López R; Díez-Campelo M; Sánchez-Guijo F; Pérez-López E; Guerrero C; Alberca I; Del Cañizo MC; Pérez-Simón JA; González-Porras JR; Caballero D
    Bone Marrow Transplant; 2014 May; 49(5):684-90. PubMed ID: 24566710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG).
    Lai YR; Chen YH; Hu DM; Jiang M; Liu QF; Liu L; Hou J; Schwarzenberger P; Li QC; Zhang ZM; Liu KY; Huang XJ
    J Hematol Oncol; 2014 Aug; 7():59. PubMed ID: 25139202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
    Cutler C; Li S; Ho VT; Koreth J; Alyea E; Soiffer RJ; Antin JH
    Blood; 2007 Apr; 109(7):3108-14. PubMed ID: 17138818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia.
    Sano H; Mochizuki K; Kobayashi S; Ohara Y; Ito M; Waragai T; Takahashi N; Ikeda K; Ohto H; Kikuta A
    Int J Hematol; 2018 Jul; 108(1):76-84. PubMed ID: 29508228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention.
    Holtzman NG; Curtis LM; Salit RB; Shaffer BC; Pirsl F; Ostojic A; Steinberg SM; Schulz E; Wilder JS; Hughes TE; Rose J; Memon S; Korngold R; Gea-Banacloche JC; Fowler DH; Hakim FT; Gress RE; Bishop MR; Pavletic SZ
    Blood Adv; 2024 Aug; 8(16):4294-4310. PubMed ID: 38669315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation.
    Arrabi L; Jan A; Hosing C; Milton DR; Yeh J
    Eur J Haematol; 2021 Dec; 107(6):634-641. PubMed ID: 34431142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.